Welcome to our dedicated page for Ekso Bionics SEC filings (Ticker: EKSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) files a range of reports and disclosure documents with the U.S. Securities and Exchange Commission that provide detailed insight into its exoskeleton and rehabilitation technology business. As a Nevada corporation listed on the Nasdaq Capital Market, the company submits annual and quarterly reports, current reports on Form 8-K, registration statements, and other filings under Commission File Number 001-37854.
Through its SEC filings, Ekso Bionics reports financial results, balance sheet details, and segment information related to its Enterprise Health and Personal Health activities. Earnings-related 8-K filings furnish press releases that discuss revenue, gross margin, operating expenses, and net loss, along with commentary on factors such as product mix between Enterprise Health and Personal Health devices and service margins. Investors can also review disclosures about cash balances, debt arrangements, and stockholders’ equity.
Current reports on Form 8-K document material events, including registered direct offerings of common stock, secured promissory note and security agreements, reverse stock split actions, and equity awards or severance arrangements for certain executives. For example, the company has filed 8-Ks describing a registered direct offering under an effective Form S-3 shelf registration statement, the terms of a secured term loan used for working capital and general corporate purposes, and the implementation and effective date of a reverse stock split intended to support compliance with Nasdaq’s minimum bid price requirements.
Other 8-K filings outline equity incentive awards, phantom performance-based restricted stock units, and change in control and severance agreements for key executives, including conditions for vesting and severance benefits. These documents provide detail on how Ekso Bionics structures compensation and protections around potential change in control events.
On this SEC filings page, users can access Ekso Bionics’ real-time submissions from the EDGAR system, including Forms 10-K and 10-Q for comprehensive financial and risk factor disclosures, as well as Form 4 and related insider transaction reports when available. AI-powered summaries help explain lengthy filings, highlight key terms in financing and equity agreements, and clarify the implications of capital markets transactions, reverse stock splits, and executive compensation arrangements for EKSO shareholders.
ChronoScale Corporation, formerly Ekso Bionics Holdings, completed its business combination with Applied Digital’s cloud subsidiary, Applied Digital Cloud Corporation, which is now a wholly owned subsidiary. The company also changed its name, fiscal year-end to May 31, and Nasdaq ticker to CHRN.
Contributor received 138,216,820 new common shares in exchange for all Cloud equity, and Applied Digital purchased 1,311,407 common shares for approximately $15.75 million in a private PIPE at $12.01 per share. After closing, Applied Digital and Contributor hold about 97% of outstanding common stock, leaving legacy Ekso holders with about 3% of 143,093,381 shares outstanding.
An Investor Rights Agreement gives Applied-related holders extensive board designation, observer, approval, preemptive and registration rights, while a services agreement entitles Applied Digital to a quarterly fee equal to 1% of ChronoScale’s gross revenue. The company adopted a 22,500,000-share 2026 Omnibus Equity Incentive Plan and appointed Ying Cenly Chen as CEO under a new offer letter, while changing auditors from WithumSmith+Brown to CBIZ CPAs.
Ekso Bionics Holdings, Inc. outlines the final steps to close its previously announced business combination with Applied Digital affiliates under a Contribution and Exchange Agreement, after which the company will be renamed ChronoScale Corporation and its stock is expected to trade on Nasdaq under the symbol “CHRN.”
As a condition to closing, Ekso entered into a Securities Purchase Agreement with Applied Digital Corporation for the APLD Parent PIPE Investment, selling 1,311,407 common shares at $12.01 per share for gross proceeds of about $15.75 million. Lake Street Capital Markets will receive a 5.0% cash fee, roughly $0.75 million, for placement services. The company also filed Second Amended and Restated Articles of Incorporation with effectiveness timed around the May 5, 2026 closing sequence.
Ekso Bionics Holdings, Inc. reported a sharp deterioration in results for the three months ended March 31, 2026 and raised substantial doubt about its ability to continue as a going concern. Revenue fell to $2,141 from $3,375, while net loss widened to $6,885 from $2,891, driven by lower device sales and higher general and administrative and sales and marketing costs.
Operating activities used $2,123 of cash, and cash and restricted cash totaled $3,993, with unrestricted cash around $3,743. Management currently estimates existing cash will fund operations only into the early part of the third quarter of 2026 and states it expects continued operating losses and negative operating cash flows.
To bolster liquidity, the company completed a January 2026 private placement of Series B Convertible Preferred Stock and warrants, generating net proceeds of about $5,265, and carries a $2,000 secured B. Riley promissory note and a $1,770 subordinated note to Parker Hannifin. New warrant liabilities of $2,863 were recorded at fair value, contributing to additional non‑cash expense.
Ekso Bionics Holdings, Inc. filed an amended annual report to add Part III disclosures, including director and executive biographies, compensation, ownership and auditor fee details, because a proxy statement will not be filed within 120 days. The amendment also updates the cover page, share count and includes refreshed CEO/CFO certifications.
As of April 2, 2026, Ekso had 3,563,381 common shares outstanding and a public float valued at $8.16 million as of June 30, 2025. In 2025, CEO Scott Davis received total compensation of $908,750, while the CFO and COO each earned under $500,000, with annual bonuses tied to revenue, cash spend and operational milestones. The company details board committee structures, independence determinations, equity incentive awards, change-in-control severance protections, a Dodd-Frank–compliant clawback policy and significant holders, including several institutions with more than 5% combined voting power.
Mink Brook reporting persons report beneficial ownership of 190,596 shares (5.4%) of Ekso Bionics common stock. As of the close of business on April 8, 2026, Mink Brook Partners LP held 190,596 shares. The filing states shared voting and shared dispositive power among Mink Brook Capital GP LLC, Mink Brook Asset Management LLC, and William Mueller. The percentage is calculated using 3,563,381 shares outstanding as of February 23, 2026 disclosed in the company’s Form 10-K; the filers include a disclaimer of beneficial ownership except to the extent of pecuniary interest.
Ekso Bionics Holdings, Inc. is notifying stockholders that holders of approximately 50.4% of voting power approved, by written consent, a business combination under which Applied Digital Cloud Corporation (“Cloud”) will be contributed to Ekso in exchange for 138,216,820 newly issued shares, making Cloud a wholly owned subsidiary.
Immediately prior to closing the Transactions, Applied Parent expects to subscribe for at least $15.0 million of common stock. Upon closing (assuming specified conversions, vesting and a $11.81 assumed PIPE price), legacy Ekso holders would hold ~3%, Contributor ~96%, and Applied Parent ~1% of the combined company, which will be renamed ChronoScale Corporation.
Ekso Bionics Holdings, Inc. is notifying holders that Principal Stockholders holding ~50.4% approved by written consent a combination that will contribute Applied Digital Cloud Corporation into Ekso in exchange for 138,216,820 newly issued shares, amend the charter to increase authorized common shares to 290,000,000, adopt the ChronoScale 2026 equity plan and permit a private $15.0M Applied Parent equity purchase. Immediately after closing (assuming full conversion and an assumed $11.81 share price) Contributor would hold ~96% of the combined company, legacy holders ~3% and Applied Parent ~1%. The Company expects to file a Nasdaq listing application for the renamed ChronoScale Corporation. Closing is conditioned on customary regulatory, listing and cash requirements and will not occur until 20 calendar days after mailing this statement.
Ekso Bionics Holdings, Inc. notified holders that Principal Stockholders holding approximately 50.4% approved by written consent a transaction to acquire Applied Digital Cloud Corporation’s business in exchange for 138,216,820 newly issued shares, amend its articles to increase authorized common stock and change its name to ChronoScale Corporation. The closing is subject to customary conditions, including Nasdaq listing approval and an Applied Parent Equity Financing expected to raise at least $15.0 million. Following closing, pro forma ownership (based on shares outstanding as of February 20, 2026) is expected to be ~96% Contributor, ~1% Applied Parent and ~3% legacy holders, assuming certain conversions, vesting and an illustrative price of $11.81 per share.
Ekso Bionics Holdings Chief Operating Officer Jason C. Jones increased his ownership through a small share acquisition tied to the company’s retirement plan. He acquired 1,308 shares of common stock on March 16, 2026 at $11.85 per share in an open-market purchase recorded under his 401(k) account, as part of the issuer’s 401(k) contribution matching program.
After this transaction, he indirectly holds 4,449 shares through the 401(k) and directly holds 25,621 shares of common stock. The share amounts disclosed have been adjusted to reflect a prior 1-for-15 reverse stock split.
Ekso Bionics Holdings, Inc. Chief Financial Officer Jerome Wong reported an open-market purchase of common stock through a 401(k) plan. He acquired 1,308 shares on March 16, 2026 at $11.85 per share, held indirectly via a 401(k) account under the company’s matching contribution program.
Following this transaction, he indirectly held 4,184 shares through the 401(k) and directly held 24,771 shares of common stock. A prior 1-for-15 reverse stock split effective on June 2, 2025 is reflected in the reported share amounts.